Literature DB >> 3377820

Immunospecific targeting of liposomes to erythrocytes.

P A Peeters1, C A Claessens, W M Eling, D J Crommelin.   

Abstract

Immunoliposomes were made by covalently linking Fab' fragments (from rabbit antimouse erythrocyte IgG) to reverse-phase evaporation vesicles (REV) via maleimido-4-(p-phenylbutyrate) phosphatidylethanolamine (MPB-PE) as anchor molecule. These immunoliposomes were characterized in terms of size, charge, stability and antigen binding capacity. The effect of the liposomal Fab' density on the interaction with the target cell was studied. Two isolation methods were tested to separate free Fab' from liposomally bound Fab'. The necessity of deactivation of remaining reactive sites with dithiothreitol preincubation to increase the specificity of immunoliposome target cell interactions was demonstrated.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3377820     DOI: 10.1016/0006-2952(88)90584-9

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  4 in total

Review 1.  Red blood cells: The metamorphosis of a neglected carrier into the natural mothership for artificial nanocarriers.

Authors:  Patrick M Glassman; Elizabeth D Hood; Laura T Ferguson; Zongmin Zhao; Don L Siegel; Samir Mitragotri; Jacob S Brenner; Vladimir R Muzykantov
Journal:  Adv Drug Deliv Rev       Date:  2021-09-29       Impact factor: 15.470

2.  Chloroquine blood levels after administration of the liposome-encapsulated drug in relation to therapy of murine malaria.

Authors:  P A Peeters; K de Leest; W M Eling; D J Crommelin
Journal:  Pharm Res       Date:  1989-09       Impact factor: 4.200

3.  Red Blood Cell Hitchhiking: A Novel Approach for Vascular Delivery of Nanocarriers.

Authors:  Jacob S Brenner; Samir Mitragotri; Vladimir R Muzykantov
Journal:  Annu Rev Biomed Eng       Date:  2021-03-31       Impact factor: 11.324

Review 4.  Liposomes for malaria management: the evolution from 1980 to 2020.

Authors:  Patrick B Memvanga; Christian I Nkanga
Journal:  Malar J       Date:  2021-07-27       Impact factor: 2.979

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.